Status:
TERMINATED
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
Lead Sponsor:
DiObex
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus. Keto...
Detailed Description
To maintain the blind in Protocol DIO-502, subjects will be re-randomized at Study Visit 1 to one of three doses of DIO-902: 150, 300 or 450 mg QHS. All subjects receiving DIO-902 placebo and 50% of s...
Eligibility Criteria
Inclusion
- Participated in DIO-502
Exclusion
- Did not participate in DIO-502
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00622089
Start Date
January 1 2008
End Date
December 1 2008
Last Update
May 28 2008
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Terence Hart
Muscle Shoals, Alabama, United States, 35662
2
Genova Research
Tucson, Arizona, United States, 85741
3
Research Solutions
Jonesboro, Arkansas, United States, 72401
4
Arkansas Primary Care Clinic
Little Rock, Arkansas, United States, 72211